GH Research PLC (GHRS)
Develops inhalable drugs to treat depression and related psychiatric disorders.
$27.96+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+103.5%
The outlook
GHRS is trading near the upper end of its 52-week range and above both its 50- and 200-day moving averages. Analyst consensus is strongly bullish, with an average price target about 43% above the current price. The stock shows upward momentum in its recent trend.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range85% of the way from its 52-week low to high
Price targetAvg target +43% vs current price
Analyst price target
~12-month · 9 analysts$40.00average target+43.1% vs now
Now $27.96
Low $32.00High $65.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.92B
52-wk high
$31.00
52-wk low
$11.32
50-day avg
$24.43
200-day avg
$17.64
Trailing P/E
—